Skip to content

Search

Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart disease

Regular intramuscular (i.m.) benzathine penicillin G (BPG) injections have been the cornerstone of rheumatic heart disease (RHD) secondary prophylaxis since the 1950s. Patient adherence to IM BPG is poor, largely due to pain, the need for regular injections every 3-4 weeks and health sector delivery challenges in resource-limited settings. There is an urgent need for new approaches for secondary prophylaxis, such as an implant which could provide sustained penicillin concentrations for more than 6 months.

Partnering with communities to reduce rheumatic heart disease in the Kimberley

The Kimberley has the highest rates of rheumatic heart disease (RHD) in Western Australia – but through the establishment of a new community-led, research-backed project known as END RHD Communities, there’s hope this will change.

Ending deadly heart disease finally within our sights

It's been a huge year for those working to eliminate rheumatic heart disease (RHD), with breakthroughs including $35M in funding to develop a Strep A vaccine.

Finding answers for Tenaya: from a sore throat to open-heart surgery

When Katrina took her daughter Tenaya to the local emergency department for the fourth time, she was determined she wouldn’t be leaving without answers.

Australia a key contributor to global commitment to end deadly rheumatic heart disease

The World Health Organisation resolution for global action to tackle rheumatic heart disease (RHD) will have significant implications for Australia, which has some of the highest rates of the disease in the world.

National honour for The Kids Director

Leading paediatrician, infectious diseases specialist and Executive Director of The Kids Research Institute Australia, Professor Jonathan Carapetis, has been recognised for his significant contribution towards medical research with the award of Member of the Order of Australia (AM).

$35 million to develop vaccine with potential to save half a million lives per year

A vaccine to prevent rheumatic heart disease (RHD) and other life-threatening conditions caused by the common Strep A bacteria is a step closer thanks to funding announced by Minister for Indigenous Health, Hon Ken Wyatt AM, MP, in Perth today.

Describing skin health and disease in urban-living Aboriginal children: co-design, development and feasibility testing of the Koolungar Moorditj Healthy Skin pilot project

Indigenous children in colonised nations experience high rates of health disparities linked to historical trauma resulting from displacement and dispossession, as well as ongoing systemic racism. Skin infections and their complications are one such health inequity, with the highest global burden described in remote-living Australian Aboriginal and/or Torres Strait Islander (hereafter respectfully referred to as Aboriginal) children. Yet despite increasing urbanisation, little is known about the skin infection burden for urban-living Aboriginal children.

Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study

Since 1955, the recommended strategy for rheumatic heart disease secondary prophylaxis has been benzathine penicillin G injections administered intramuscularly every 4 weeks. Due to dosing frequency, pain, and programmatic challenges, adherence is suboptimal. It has previously been demonstrated that BPG delivered subcutaneously at a standard dose is safe and tolerable and has favorable pharmacokinetics, setting the scene for improved regimens with less frequent administration.

Otitis media at 6-monthly assessments of Australian First Nations children between ages 12–36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines

In remote communities of northern Australia, First Nations children with hearing loss are disproportionately at risk of poor school readiness and performance compared to their peers with no hearing loss. The aim of this trial is to prevent early childhood persisting otitis media (OM), associated hearing loss and developmental delay.